Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alcon Inc (NY: ALC )

73.26 +0.02 (+0.03%)
Streaming Delayed Price Updated: 3:09 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alcon Inc

< Previous 1 2 Next >
Alcon Reports Third Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
From Alcon Inc. Investors
Via Business Wire
Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia
From Alcon Inc. Investors
Via Business Wire
Alcon Inc. (NYSE: ALC) Highlighted for Surprising Price Action
Via Investor Brand Network
Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
From Alcon Inc. Corporate
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams
From Alcon Inc. Corporate
Via Business Wire
Alcon Reports Second Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
Lifecore Biomedical Enters into $150.0 Million in New Financing, Repays its Outstanding Term Loans and Signs New Supply Agreement to Expand HA Fermentation Capacity with Existing Long-Term Customer
New $150 million credit arrangements include six-year credit agreement and equipment sale and leaseback to replace existing term loan 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Alcon Advances Company’s Social Impact Through Global Volunteerism
From Alcon Inc. Corporate
Via Business Wire
Alcon Reports First Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2023 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivity
From Alcon Inc. Investors
Via Business Wire
Alcon Publishes Agenda for 2023 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon’s “The Lens” Interactive Compliance Training Experience Receives Coveted Anthem Award
From Alcon Inc. Corporate
Via Business Wire
Alcon to Host 2023 Capital Markets Day
From Alcon Inc. Investors
Via Business Wire
Alcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023
From Alcon Inc. Corporate
Via Business Wire
Alcon Reports Fourth Quarter and Full Year 2022 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices
From Alcon Inc. Investors
Via Business Wire
Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism
From Alcon Inc. Investors
Via Business Wire
Alcon to Present at 2023 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Alcon Prices US$1.3 Billion Senior Notes Offering
From Alcon Inc. Investors
Via Business Wire
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Third Quarter 2022 Results
From Alcon Inc. Investors
Via Business Wire
Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22
From Alcon Inc. Investors
Via Business Wire
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
From Alcon Inc. Investors
Via Business Wire
Alcon Reports Second Quarter 2022 Results
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.